Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HLX208 in metastatic colorectal cancer
NCT05127759Phase 2Unknown
- Sponsor
- Henlius
- Start
- Mar 2022
- Primary completion
- Jan 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of HLX208 in metastatic colorectal cancer (mCRC), sponsored by Henlius. Primary endpoint: Objective Response Rate up to 2 years. Status: unknown.
02
Drugs
HLX208
03
Conditions
metastatic colorectal cancer (mCRC)
Beyond the preview
Go deeper on NCT05127759.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05127759.